scispace - formally typeset
B

Beat Thürlimann

Researcher at University of St. Gallen

Publications -  114
Citations -  14812

Beat Thürlimann is an academic researcher from University of St. Gallen. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 36, co-authored 114 publications receiving 13695 citations. Previous affiliations of Beat Thürlimann include Harvard University & Kantonsspital St. Gallen.

Papers
More filters
Journal ArticleDOI

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

O. Abe, +412 more
- 14 May 2005 - 
TL;DR: The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.
Journal ArticleDOI

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007

TL;DR: An expert Panel reaffirmed the primary importance of determining endocrine responsiveness of the cancer as a first approach to selecting systemic therapy and recommended the use of high-quality standard histopathological assessment for both risk allocation and target identification.
Journal ArticleDOI

Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

TL;DR: Together with the lower observed incidence of thromboembolic events and vaginal bleeding, these findings indicate that anastrozole should be considered as first-line therapy for postmenopausal women with ABC.
Journal ArticleDOI

Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer

TL;DR: This account of the highlights of the eighth St Gallen (Switzerland) meeting in 2003 emphasizes new information that has emerged during the 2 years since the seventh meeting in 2001, and highlights the separate nature of endocrine-nonresponsive breast cancer and the promise of newly defined prognostic and predictive markers.